Results 111 to 120 of about 2,479 (207)

Severe acute allergic reaction after switching anti-calcitonin gene-related peptide monoclonal antibodies: A case report

Cephalalgia Reports
Background Anti-calcitonin gene-related peptide monoclonal antibodies (CGRP-mAbs) are widely used for migraine prevention and are generally considered safe, with rare severe allergic reactions.
Ikko Wada, Atsushi Shima, Yuu Tatsuoka, Shintaro Toda, Mahito Yamada, Yasumasa Yamamoto   +5 more
doaj   +1 more source

Comparison of Early-onset Efficacy of Anti-calcitonin Gene-related Peptide Monoclonal Antibodies for Patients with Migraine in Real-world Clinical Practice: Study Protocol for an Exploratory Clinical Trial

Neurologia Medico-Chirurgica
Three anti-calcitonin gene-related peptide monoclonal antibodies (CGRP-mAbs) are available in Japan: galcanezumab, fremanezumab, and erenumab. Early-onset efficacy has been demonstrated for each CGRP-mAb in comparison with placebo, but differences among ...
Takafumi TANEI, Satoshi MAESAWA, Yusuke NISHIMURA, Tomotaka ISHIZAKI, Yoshitaka NAGASHIMA, Miki HASHIDA, Shun YAMAMOTO, Masahiko ANDO, Yachiyo KUWATSUKA, Atsushi HASHIZUME, Toshihiko WAKABAYASHI, Ryuta SAITO   +11 more
doaj   +1 more source

Monoclonal antibodies for migraine: an update [PDF]

, 2018
Castle, Daniel, Robertson, Neil P.
core   +2 more sources

Monthly Versus Quarterly Fremanezumab in Real Life: A Comparison of Effectiveness, Tolerability, and Adherence [PDF]

Background: While clinical trials have shown no differences between monthly and quarterly regimens of fremanezumab, limited real-life data exist for comparison. This study is aimed at comparing treatment regimens in real life.Methods: This observational,
Campdelacreu, Jaume, Campdelacreu, Jaume, Campoy, Sergio, Campoy, Sergio, Huerta-villanueva, Mariano, Huerta-villanueva, Mariano, María García-sánchez, Sonia, María García-sánchez, Sonia, Miguel Cano Sánchez, Luis, Miguel Cano Sánchez, Luis, Muñoz-vendrell, Albert, Muñoz-vendrell, Albert, Prat, Joan, Prat, Joan   +13 more
core   +1 more source

Treatment of migraine with fremanezumab and sleep: A preliminary case series

Cephalalgia Reports
Background Migraine is a prevalent neurological disease that has socioeconomic and functional impact. It is also frequently associated with sleep disorders.
Agustin Melo-Carrillo, Joaquin Gorrissen, Amanda Macone, Rami Burstein, Sait Ashina   +4 more
doaj   +1 more source

Fremanezumab in real-life clinical practice: specialized headache center experience

Неврология, нейропсихиатрия, психосоматика
Anti-CGRP monoclonal antibodies (mAb) have been approved and successfully used in Russia since 2020.Objective: to investigate the efficacy and safety of fremanezumab (FRE) therapy (225 mg monthly or 675 mg quarterly) in real-life clinical practice in ...
Yu. E. Azimova, K. V. Skorobogatikh, V. V. Osipova, D. Z. Korobkova, N. V. Vashchenko, E. Z. Mamkhegov, A. S. Galanina, E. A. Guziy   +7 more
doaj   +1 more source

Ion channels in migraine disorders [PDF]

, 2018
Pietrobon, Daniela
core   +1 more source

Monoclonal antibodies against CGRP in migraine prevention: current state of knowledge

Quality in Sport
Background. Migraine is one of the most common neurological disorders and has a significant impact on patients’ quality of life. In recent years, growing attention has been directed toward targeted therapies focused on the calcitonin gene-related ...
Marcin Wieleba, Katarzyna Wiktoria Witczak, Weronika Maria Woźniak, Zuzanna Winiarska, Eliza Wiercioch, Franciszek Włodarczyk, Barbara Izabela Krupska, Magdalena Zapalska, Lidia Kulig, Julia Anna Malec   +9 more
doaj   +1 more source

Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene–related peptide monoclonal antibodies [PDF]

Antibodies; Gepant; Migraine disordersAnticuerpos; Gepant; Trastornos de migrañaAnticossos; Gepant; Trastorns de migranyaBackground To evaluate the benefit-risk assessment of atogepant and calcitonin gene–related peptide (CGRP) monoclonal antibodies ...
Ailani, Jessica, Halker Singh, Rashmi, Holle-Lee, Dagny, Kelton, Kari, Lalla, Anjana, Nagy, Krisztian, Pozo-Rosich, Patricia   +6 more
core   +1 more source

Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of Fremanezumab in Children and Adolescents with Migraine. [PDF]

Eur J Drug Metab Pharmacokinet
Iannone LF, Romozzi M, Papetti L, Toldo I, Valeriani M, Geppetti P.   +5 more
europepmc   +1 more source